Evidence map›Paper›PMID 35158790›Full record

ArticleCancers2022

NanoString Digital Molecular Profiling of Protein and microRNA in Rhabdomyosarcoma.

Atif A Ahmed, Midhat S Farooqi, Sultan S Habeebu, Elizabeth Gonzalez, Terrie G Flatt, Ashley L Wilson, Frederic G Barr

Abstract read
In one paragraph

Article in Cancers, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Atif A AhmedDepartment of Pathology and Laboratory Medicine, Children's Mercy Hospital, Kansas City, MO 64108, USA.ORCID 0000-0002-8791-5785
Midhat S FarooqiDepartment of Pathology and Laboratory Medicine, Children's Mercy Hospital/University of Missouri, Kansas City, MO 64108, USA.
Sultan S HabeebuDepartment of Pathology and Laboratory Medicine, Children's Mercy Hospital/University of Missouri, Kansas City, MO 64108, USA.
Elizabeth GonzalezDepartment of Pediatric Hematology-Oncology, Children's Mercy Hospital/University of Missouri, Kansas City, MO 64108, USA.
Terrie G FlattDepartment of Pediatric Hematology-Oncology, Children's Mercy Hospital/University of Missouri, Kansas City, MO 64108, USA.
Ashley L WilsonSeattle Children's Research Institute, Seattle, WA 98101, USA.
Frederic G BarrLaboratory of Pathology, National Cancer Institute, Bethesda, MD 20892, USA.

Funding

Epigenetic studies in rhabdomyosarcomaZIABC011423 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI BARR, FREDERIC · 2012 to 2025
$7.1M
6 · The paper itself

Abstract

purposeRhabdomyosarcoma (RMS) exhibits a complex prognostic algorithm based on histologic, biologic and clinical parameters. The embryonal (ERMS) and spindle cell-sclerosing RMS (SRMS) histologic subtypes warrant further studies due to their heterogenous genetic background and variable clinical behavior. NanoString digital profiling methods have been previously highlighted as robust novel methods to detect protein and microRNA expression in several cancers but not in RMS. METHODS/PATIENTS: To identify prognostic biomarkers, we categorized 12 ERMS and SRMS tumor cases into adverse (

resultsThe detectable expression of several component members of the PI3K/AKT, MAPK and apoptosis signaling pathways was highlighted in RMS, including INPP4B, Pan-AKT, MET, Pan-RAS, EGFR, phospho-p90 RSK, p44/42 ERK1/2, BAD, BCL-XL, cleaved caspase-9, NF1, PARP and p53. Compared to cases with favorable prognosis, the adverse-prognosis tumor samples had significantly increased expression of INPP4B, which was confirmed with traditional immunohistochemistry. The analysis of microRNA profiles revealed that, out of 798 microRNAs assessed, 228 were overexpressed and 134 downregulated in the adverse prognosis group. Significant over-expression of oncogenic/tumor suppressor miR-3144-3p, miR-612, miR-302d-3p, miR-421, miR-548ar-5p and miR-548y (

conclusionThis study highlights the utility of NanoString digital profiling methods in RMS, where it can detect distinct molecular signatures with the expression of signaling pathways and microRNAs from FFPE tumor tissue that may help identify prognostic biomarkers of interest. The overexpression of INPP4B and miR-3144-3p, miR-612, miR-302d-3p, miR-421, miR-548y and miR-548ar-5p may be associated with worse overall survival in ERMS and SRMS.

Indexed as

digital spatial profilingmicroRNANanoStringPI3K/AKTrhabdomyosarcoma

Identifiers

PMID35158790
PMCPMC8833805

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.